Edition:
United States

Biotechnology & Medical Research

Page 2

Poxel H1 net loss narrows to 9.7 million euros

Thursday, 21 Sep 2017 11:45am EDT

Sept 21 (Reuters) - POXEL SA ::H1 NET LOSS EUR 9.7‍​ MILLION VERSUS LOSS OF EUR 12.4 MILLION YEAR AGO.H1 REVENUE NO REVENUE VERSUS NO TURNOVER YEAR AGO.H1 OPERATING LOSS EUR ‍​9.5 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.AS OF JUNE 30, 2017, CASH AND CASH EQUIVALENTS WERE EUR €34.9 MILLION‍​.PLANS TO MOVE FORWARD WITH ITS IMEGLIMIN PHASE 3 PROGRAM DURING Q4 2017‍​.

CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​

Thursday, 21 Sep 2017 09:00am EDT

Sept 21 (Reuters) - CytRx Corp :CytRx Corp - proxy advisory firm Glass Lewis & Co. Recommends CytRx Corp stockholders vote "for" proposed reverse stock split​.

Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

Thursday, 21 Sep 2017 08:00am EDT

Sept 21 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy.Says ‍preliminary data from ASPIRO expected to be available in Q4 of 2017​.Says ‍Audentes plans to announce preliminary data from INCEPTUS in Q3 of 2017​.

Spectral provides regulatory update on its PMA submission for Toraymyxin

Thursday, 21 Sep 2017 08:00am EDT

Sept 21 (Reuters) - Spectral Medical Inc :Spectral provides regulatory update on its PMA submission for Toraymyxin(TM).Spectral Medical Inc - ‍has been engaged in an ongoing interactive review process with FDA​.Spectral Medical Inc - ‍expects to receive more detailed feedback from FDA on PMA submission in Q4 of 2017​.Spectral Medical -continues to be involved in a review process with FDA and Health Canada for its SAM continuous renal replacement therapy instrument.

China Regenerative Medicine International say Dai Yumin acquired 40 pct stake in All Favour

Thursday, 21 Sep 2017 07:36am EDT

Sept 21 (Reuters) - China Regenerative Medicine International Ltd <8158.HK>:Voluntary announcement Dai Yumin acquired 40% All Favour and became the sole beneficial owner of All Favour.Deal at a consideration of approximately HK$340 million.

Tella says transfer of entire 44.4 pct stake in consolidated subsidiary for 110 mln yen

Thursday, 21 Sep 2017 02:54am EDT

Sept 21(Reuters) - Tella Inc <2191.T>:Says it sells entire shares (44.4 percent stake) of an Osaka-based cell processing facilities consolidated subsidiary, for 110 million yen, on Sept. 21.

Morphosys says to receive milestone payments from Janssen

Thursday, 21 Sep 2017 01:30am EDT

Sept 21 (Reuters) - Morphosys AG :Says announces that its licensee Janssen has initiated two phase 3 studies with TremfyaTM (guselkumab) in psoriatic arthritis.Says will receive a milestone payment from Janssen in connection with start of phase 3 development in PSA.Says financial details were not disclosed.

Acceleron announces pricing of public offering of common stock

Wednesday, 20 Sep 2017 08:31pm EDT

Sept 20 (Reuters) - Acceleron Pharma Inc :Acceleron announces pricing of public offering of common stock.Acceleron Pharma - Announced underwritten public offering of 5.4 million shares of common stock at a price to public of $37 per share.

Sirtex Medical ‍complies with ASIC infringement notice

Wednesday, 20 Sep 2017 06:28pm EDT

Sept 21 (Reuters) - Sirtex Medical Ltd ::Complies with ASIC infringement notice ​.Infringement notice alleged that certain information contained in trading update should have been released by co on 21 Nov 2016​.Denies ASIC allegation​.

Abivax H1 net loss narrows to 5.5 million euros

Wednesday, 20 Sep 2017 12:31pm EDT

Sept 20 (Reuters) - ABIVAX SA ::‍H1 2017 NET LOSS OF EUR 5.5M VERSUS EUR 8.3 IN H1 2016​.SAYS IS FULLY FUNDED THROUGH Q3 2018, BASED ON ASSESSMENT OF PLANNED RESEARCH AND DEVELOPMENT NEEDS.‍IN Q4 2017 WE WILL BEGIN ENROLLING FIRST CLINICAL PROOF-OF-CONCEPT STUDY OF ABX464 IN ULCERATIVE COLITIS PATIENTS​.H1 OPERATING LOSS EUR ‍​7.4 MILLION VERSUS LOSS OF EUR 10.6 MILLION YEAR AGO.‍REVENUES, WHICH WERE COMPRISED MAINLY OF A RESEARCH TAX CREDIT, DECREASED TO EUR 1.9M IN H1 2017, COMPARED TO EUR 2.5M IN H1 2016​.END-H1 NET FINANCIAL POSITION EUR 16.1 MILLION VERSUS EUR 22.8 MILLION YEAR AGO.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary